Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
SAN DIEGO , July 30, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Noah L. Rosenberg , M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline. Dr. Rosenberg brings to Retrophin more than 20 years of
View HTML
Toggle Summary Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan
Patients continue to enroll in Phase 3 FORT Study of fosmetpantotenate in PKAN and Phase 3 DUPLEX Study of sparsentan in FSGS Phase 2 proof-of-concept study of CNSA-001 in patients with PKU set to initiate; top-line results expected in early 2019 Retrophin Chief Executive Officer Stephen Aselage
View HTML
Toggle Summary Retrophin to Report Second Quarter 2018 Financial Results
SAN DIEGO , July 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2018 financial results on Thursday, July 26, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued U.S. Patent
SAN DIEGO , June 14, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent covering the Company’s product candidate sparsentan which, in addition to being in Phase 3 clinical development for the
View HTML
Toggle Summary Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients
Independent Data Monitoring Committee’s (DMC) review of available safety data supports continuing with study as planned; FORT Study now open to pediatric patients aged 6 to 17 Top-line data anticipated in the second half of 2019 SAN DIEGO , June 04, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , May 24, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in June: Jefferies 2018 Global Healthcare Conference Date: Thursday, June 7, 2018 Time: 9:00 a.m.
View HTML
Toggle Summary Retrophin Receives Workplace Excellence Award
Peter Barron Stark Companies honors Retrophin for its continued commitment to workplace and cultural excellence SAN DIEGO , May 23, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been awarded the Peter Barron Stark Companies ( PBS ) Award for Workplace Excellence
View HTML
Toggle Summary Retrophin Reports First Quarter 2018 Financial Results
Company obtains FDA and EMA feedback on pathway to NDA and MAA filing for sparsentan in IgA nephropathy; single Phase 3 trial expected to initiate in the fourth quarter of 2018 Pivotal Phase 3 DUPLEX Study of sparsentan in FSGS underway to support Subpart H NDA filing Revenue rose 14 percent to $38
View HTML
Toggle Summary Retrophin to Report First Quarter 2018 Financial Results
SAN DIEGO , April 17, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
SAN DIEGO , April 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of focal segmental
View HTML